Aprilbio Co., Ltd. 397030

KRX · South Korea · Health Technology

KRW 21,300.00+1,100.00 (+5.45%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Company news

Yahoo FinanceFeb 11, 2026

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.